Role of the proteasome in excitotoxicity-induced cleavage of glutamic acid decarboxylase in cultured hippocampal neurons

PLoS ONE

Volumn 5, Issue 4, 2010, Pages

  Baptista, Márcio S ^a   Melo, Carlos V ^a,d   Armelão, Ḿr ^a   Herrmann, Dennis ^a   Pimentel, Diogo O ^a   Leal, Graciano ^a   Caldeira, Margarida V ^a   Bahr, Ben A ^b   Bengtson, Mário R ^c   Almeida, Ramiro D ^a   Duarte, Carlos B ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF NORTH CAROLINA AT PEMBROKE   (United States)

^c GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CALPAIN; GLUTAMATE DECARBOXYLASE 65; GLUTAMATE DECARBOXYLASE 67; GLUTAMIC ACID; LACTACYSTIN; MESSENGER RNA; PROTEASOME; PROTEASOME INHIBITOR; RECOMBINANT GLUTAMATE DECARBOXYLASE 65; UBEI 41; UNCLASSIFIED DRUG; YU 102; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 1; GLUTAMATE DECARBOXYLASE 2;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN NERVE CELL; CELL DEATH; CEREBELLUM; CONTROLLED STUDY; DEREGULATION; EMBRYO; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME LOCALIZATION; GABAERGIC TRANSMISSION; HIPPOCAMPUS; NERVE CELL LESION; NERVE CELL STIMULATION; NEURITE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN BINDING; RAT; UBIQUITINATION; ANIMAL; CELL CULTURE; CYTOLOGY; DRUG EFFECT; ENZYMOLOGY; HYDROLYSIS; METABOLISM; NERVE CELL;

ANIMALS; CELLS, CULTURED; GLUTAMATE DECARBOXYLASE; GLUTAMIC ACID; HIPPOCAMPUS; HYDROLYSIS; NEURONS; PROTEASOME ENDOPEPTIDASE COMPLEX; RATS; UBIQUITINATION;

EID: 77956333111     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010139     Document Type: Article

References (77)

1. Lipton SA, Rosenberg PA (1994) Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 330: 613-622.
2. Choi DW (1988) Glutamate neurotoxicity and diseases of the nervous system, Neuron 1: 623-634.
3. Gardoni F, Di Luca M (2006) New targets for pharmacological intervention in the glutamatergic synapse. Eur J Pharmacol 545 (2006): 2-10.
4. Lewen A, Li GL, Olsson Y, Hillered L (1996) Changes in microtubule-associated protein 2 and amyloid precursor protein immunoreactivity following traumatic brain injury in rat: influence of MK-801 treatment. Brain Res 719: 161-171.
5. Carvalho AP, Ferreira IL, Carvalho AL, Duarte CB (1995) Glutamate receptor modulation of [3H]GABA release and intracellular calcium in chick retina cells. Ann N Y Acad Sci 757: 439-456.
6. Saransaari P, Oja SS (2008) GABA release under normal and ischemic conditions. Neurochem Res 33: 962-969.
7. Schwartz-Bloom RD, Sah R (2001) gamma-Aminobutyric acidA neurotransmission and cerebral ischemia. J Neurochem 77: 353-371.
8. Vemuganti R (2005) Decreased expression of vesicular GABA transporter, but not vesicular glutamate, acetylcholine and monoamine transporters in rat brain following focal ischemia. Neurochem Int 47: 136-142.
9. Baliova M, Knab A, Franekova V, Jursky F (2009) Modification of the cytosolic regions of GABA transporter GAT1 by calpain. Neurochem Int 55: 288-294.
10. Bevers MB, Neumar RW (2008) Mechanistic role of calpains in postischemic neurodegeneration. J Cereb Blood Flow Metab 28: 655-673.
11. Martin DL, Rimvall K (1993) Regulation of gamma-aminobutyric acid synthesis in the brain, J Neurochem 60: 395-407.
12. Erlander MG, Tillakaratne NJ, Feldblum S, Patel N, Tobin AJ (1991) Two genes encode distinct glutamate decarboxylases. Neuron 7: 91-100.
13. Sheikh SN, Martin SB, Martin DL (1999) Regional distribution and relative amounts of glutamate decarboxylase isoforms in rat and mouse brain. Neurochem Int 35: 73-80.
14. Hsu CC, Thomas C, Chen W, Davis KM, Foos T, et al. (1999) Role of synaptic vesicle proton gradient and protein phosphorylation on ATP-mediated activation of membrane-associated brain glutamate decarboxylase. J Biol Chem 274: 24366-24371.
15. Nathan B, Floor E, Kuo CY, Wu JY (1995) Synaptic vesicle-associated glutamate decarboxylase: identification and relationship to insulin-dependent diabetes mellitus. J Neurosci Res 40: 134-137.
16. Reetz A, Solimena M, Matteoli M, Folli F, Takei K, et al. (1991) GABA and pancreatic beta-cells: colocalization of glutamic acid decarboxylase (GAD) and GABA with synaptic-like microvesicles suggests their role in GABA storage and secretion. EMBO J 10: 1275-1284.
17. Jin H, Wu H, Osterhaus G, Wei J, Davis K, et al. (2003) Demonstration of functional coupling between gamma -aminobutyric acid (GABA) synthesis and vesicular GABA transport into synaptic vesicles, Proc Natl Acad Sci U S A 100: 4293-4298.
18. Wu H, Jin Y, Buddhala C, Osterhaus G, Cohen E, et al. (2007) Role of glutamate decarboxylase (GAD) isoform, GAD65, in GABA synthesis and transport into synaptic vesicles-Evidence from GAD65-knockout mice studies. Brain Res 1154: 80-83.
19. Asada H, Kawamura Y, Maruyama K, Kume H, Ding R, et al. (1996) Mice lacking the 65 kDa isoform of glutamic acid decarboxylase (GAD65) maintain normal levels of GAD67 and GABA in their brains but are susceptible to seizures. Biochem Biophys Res Commun 229: 891-895.
20. Kaufman DL, Houser CR, Tobin AJ (1991) Two forms of the gammaaminobutyric acid synthetic enzyme glutamate decarboxylase have distinct intraneuronal distributions and cofactor interactions. J Neurochem 56: 720-723.
21. Lernmark A (1996) Glutamic acid decarboxylase-gene to antigen to disease. J Intern Med 240: 259-277.
22. Sha D, Jin Y, Wu H, Wei J, Lin CH, et al. (2008) Role of mu-calpain in proteolytic cleavage of brain L-glutamic acid decarboxylase. Brain Res 1207:9-18.
23. Wei J, Lin CH, Wu H, Jin Y, Lee YH, et al. (2006) Activity-dependent cleavage of brain glutamic acid decarboxylase 65 by calpain. J Neurochem 98: 1688-1695.
24. Monnerie H, Le Roux PD (2008) Glutamate alteration of glutamic acid decarboxylase (GAD) in GABAergic neurons: the role of cysteine proteases. Exp Neurol 213: 145-153.
25. Monnerie H, Le Roux PD (2007) Reduced dendrite growth and altered glutamic acid decarboxylase (GAD) 65- and 67-kDa isoform protein expression from mouse cortical GABAergic neurons following excitotoxic injury in vitro. Exp Neurol 205: 367-382.
26. Vanderklish PW, Bahr BA (2000) The pathogenic activation of calpain: a marker and mediator of cellular toxicity and disease states. Int J Exp Pathol 81:323-339.
27. Herrmann J, Lerman LO, Lerman A (2007) Ubiquitin and ubiquitin-like proteins in protein regulation. Circ Res 100: 1276-1291.
28. Hershko A, Ciechanover A (1998) The ubiquitin system. Annu Rev Biochem 67: 425-479.
29. Ge P, Luo Y, Liu CL, Hu B (2007) Protein aggregation and proteasome dysfunction after brain ischemia. Stroke 38: 3230-3236.
30. Asai A, Tanahashi N, Qiu JH, Saito N, Chi S, et al. (2002) Selective proteasomal dysfunction in the hippocampal CA1 region after transient forebrain ischemia. J Cereb Blood Flow Metab 22: 705-710.
31. Phillips JB, Williams AJ, Adams J, Elliott PJ, Tortella FC (2000) Proteasome inhibitor PS519 reduces infarction and attenuates leukocyte infiltration in a rat model of focal cerebral ischemia. Stroke 31: 1686-1693.
32. Williams AJ, Hale SL, Moffett JR, Dave JR, Elliott PJ, et al. (2003) Delayed treatment with MLN519 reduces infarction and associated neurologic deficit caused by focal ischemic brain injury in rats via antiinflammatory mechanisms involving nuclear factor-kappaB activation, gliosis, and leukocyte infiltration. J Cereb Blood Flow Metab 23: 75-87.
33. Zhang L, Zhang ZG, Zhang RL, Lu M, Adams J, et al. (2001) Postischemic (6- Hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia. Stroke 32: 2926-2931.
34. Solimena M, Dirkx Jr. R, Radzynski M, Mundigl O, De Camilli P (1994) A signal located within amino acids 1-27 of GAD65 is required for its targeting to the Golgi complex region. J Cell Biol 126: 331-341.
35. Santos AR, Duarte CB (2008) Validation of internal control genes for expression studies: effects of the neurotrophin BDNF on hippocampal neurons. J Neurosci Res 86: 3684-3692.
36. Kubista K, Sindelka R, Tichopad A, Bergkvist A, Lindh D, et al. (2007) The prime technique: real-time PCR data analysis, G.I.T. Laboratory Journal 9: 2.
37. Bahr BA (2000) Integrin-type signaling has a distinct influence on NMDAinduced cytoskeletal disassembly. J Neurosci Res 59: 827-832.
38. Munirathinam S, Rogers G, Bahr BA (2002) Positive modulation of alphaamino- 3-hydroxy-5-methyl-4-isoxazolepropionic acid-type glutamate receptors elicits neuroprotection after trimethyltin exposure in hippocampus. Toxicol Appl Pharmacol 185: 111-118.
39. Frick KM, Burlingame LA, Delaney SS, Berger-Sweeney J (2002) Sex differences in neurochemical markers that correlate with behavior in aging mice. Neurobiol Aging 23: 145-158.
40. Almeida RD, Manadas BJ, Melo CV, Gomes JR, Mendes CS, et al. (2005) Neuroprotection by BDNF against glutamate-induced apoptotic cell death is mediated by ERK and PI3-kinase pathways. Cell Death Differ 12: 1329-1343.
41. Duarte CB, Ferreira IL, Santos PF, Oliveira CR, Carvalho AP (1993) Glutamate increases the [Ca2+]i but stimulates Ca2+ -independent release of [3H]GABA in cultured chick retina cells. Brain Res 611: 130-138.
42. Swanwick CC, Harrison MB, Kapur J (2004) Synaptic and extrasynaptic localization of brain-derived neurotrophic factor and the tyrosine kinase B receptor in cultured hippocampal neurons. J Comp Neurol 478: 405-417.
43. Kisselev AF, Goldberg AL (2001) Proteasome inhibitors: from research tools to drug candidates. Chem Biol 8: 739-758.
44. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, et al. (1994) Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78: 761-771.
45. Myung J, Kim KB, Crews CM (2001) The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev 21: 245-273.
46. Rideout HJ, Stefanis L (2002) Proteasomal inhibition-induced inclusion formation and death in cortical neurons require transcription and ubiquitination. Mol Cell Neurosci 21: 223-238.
47. Butts BD, Hudson HR, Linseman DA, Le SS, Ryan KR, et al. (2005) Proteasome inhibition elicits a biphasic effect on neuronal apoptosis via differential regulation of pro-survival and pro-apoptotic transcription factors. Mol Cell Neurosci 30: 279-289.
48. Myung J, Kim KB, Lindsten K, Dantuma NP, Crews CM (2001) Lack of proteasome active site allostery as revealed by subunit-specific inhibitors. Mol Cell 7: 411-420.
49. Yang Y, Kitagaki J, Dai RM, Tsai YC, Lorick KL, et al. (2007) Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics. Cancer Res 67: 9472-9481.
50. Caba E, Brown QB, Kawasaki B, Bahr BA (2002) Peptidyl alpha-keto amide inhibitor of calpain blocks excitotoxic damage without affecting signal transduction events. J Neurosci Res 67: 787-794.
51. Sorokin AV, Selyutina AA, Skabkin MA, Guryanov SG, Nazimov IV, et al. (2005) Proteasome-mediated cleavage of the Y-box-binding protein 1 is linked to DNA-damage stress response. EMBO J 24: 3602-3612.
52. Baugh JM, Pilipenko EV (2004) 20S proteasome differentially alters translation of different mRNAs via the cleavage of eIF4F and eIF3. Mol Cell 16: 575-586.
53. Martin SB, Waniewski RA, Battaglioli G, Martin DL (2003) Post-mortem degradation of brain glutamate decarboxylase, Neurochem Int 42: 549-554.
54. Hsu CC, Davis KM, Jin H, Foos T, Floor E, et al. (2000) Association of Lglutamic acid decarboxylase to the 70-kDa heat shock protein as a potential anchoring mechanism to synaptic vesicles, J Biol Chem 275: 20822-20828.
55. Esclapez M, Tillakaratne NJ, Kaufman DL, Tobin AJ, Houser CR (1994) Comparative localization of two forms of glutamic acid decarboxylase and their mRNAs in rat brain supports the concept of functional differences between the forms, J Neurosci 14: 1834-1855.
56. Battaglioli G, Liu H, Hauer CR, Martin DL (2005) Glutamate decarboxylase: loss of N-terminal segment does not affect homodimerization and determination of the oxidation state of cysteine residues, Neurochem Res 30, 989-1001.
57. Fenalti G, Law RH, Buckle AM, Langendorf C, Tuck K, et al. (2007) GABA production by glutamic acid decarboxylase is regulated by a dynamic catalytic loop. Nat Struct Mol Biol 14: 280-286.
58. Salin P, Chesselet MF (1993) Expression of GAD (Mr 67,000) and its messenger RNA in basal ganglia and cerebral cortex after ischemic cortical lesions in rats. Exp Neurol 119: 291-301.
59. Qin ZH, Zhang SP, Weiss B (1994) Dopaminergic and glutamatergic blocking drugs differentially regulate glutamic acid decarboxylase mRNA in mouse brain. Brain Res Mol Brain Res 21: 293-302.
60. Jackman RW, Kandarian SC (2004) The molecular basis of skeletal muscle atrophy. Am J Physiol Cell Physiol 287: C834-843.
61. Bartoli M, Richard I (2005) Calpains in muscle wasting. Int J Biochem Cell Biol 37: 2115-2133.
62. Alkalay I, Yaron A, Hatzubai A, Orian A, Ciechanover A, et al. (1995) Stimulation-dependent I kappa B alpha phosphorylation marks the NF-kappa B inhibitor for degradation via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A 92: 10599-10603.
63. Scherer DC, Brockman JA, Chen Z, Maniatis T, Ballard DW (1995) Signalinduced degradation of I kappa B alpha requires site-specific ubiquitination. Proc Natl Acad Sci U S A 92: 11259-11263.
64. Chen F, Lu Y, Kuhn DC, Maki M, Shi X, et al. (1997) Calpain contributes to silica-induced I kappa B-alpha degradation and nuclear factor-kappa B activation. Arch Biochem Biophys 342: 383-388.
65. Di Napoli M, McLaughlin B (2005) The ubiquitin-proteasome system as a drug target in cerebrovascular disease: therapeutic potential of proteasome inhibitors. Curr Opin Investig Drugs 6: 686-699.
66. Ray SK (2006) Currently evaluated calpain and caspase inhibitors for neuroprotection in experimental brain ischemia. Curr Med Chem 13: 3425-3440.
67. Noga M, Hayashi T (1996) Ubiquitin gene expression following transient forebrain ischemia. Brain Res Mol Brain Res 36: 261-267.
68. Vannucci SJ, Mummery R, Hawkes RB, Rider CC, Beesley PW (1998) Hypoxia-ischemia induces a rapid elevation of ubiquitin conjugate levels and ubiquitin immunoreactivity in the immature rat brain. J Cereb Blood Flow Metab 18: 376-385.
69. Liu CL, Martone ME, Hu BR (2004) Protein ubiquitination in postsynaptic densities after transient cerebral ischemia. J Cereb Blood Flow Metab 24:1219-1225.
70. Shah IM, Lees KR, Pien CP, Elliott PJ (2002) Early clinical experience with the novel proteasome inhibitor PS-519. Br J Clin Pharmacol 54: 269-276.
71. Wei J, Jin Y, Wu H, Sha D, Wu JY (2003) Identification and functional analysis of truncated human glutamic acid decarboxylase 65. J Biomed Sci 10: 617-624.
72. Wei J, Wu JY (2008) Post-translational regulation of L-glutamic acid decarboxylase in the brain. Neurochem Res 33: 1459-1465.
73. De Almeida OM, Gardino PF, Loureiro dos Santos NE, Yamasaki EN, de Mello MC, et al. (2002) Opposite roles of GABA and excitatory amino acids on the control of GAD expression in cultured retina cells, Brain Res 925: 89-99.
74. de Mello FG, Hokoc JN, Ventura AL, Gardino PF (1991) Glutamic acid decarboxylase of embryonic avian retina cells in culture: regulation by gammaaminobutyric acid (GABA). Cell Mol Neurobiol 11: 485-496.
75. Kanaani J, el-HusseiniAel -D, Aguilera-Moreno A, Diacovo JM, Bredt DS, et al. (2002) A combination of three distinct trafficking signals mediates axonal targeting and presynaptic clustering of GAD65. J Cell Biol 158: 1229-1238.
76. Kanaani J, Patterson G, Schaufele F, Lippincott-Schwartz J, Baekkeskov S (2008) A palmitoylation cycle dynamically regulates partitioning of the GABAsynthesizing enzyme GAD65 between ER-Golgi and post-Golgi membranes, J Cell Sci 121: 437-449.
77. Soghomonian JJ, Martin DL (1998) Two isoforms of glutamate decarboxylase: why? Trends Pharmacol Sci 19: 500-505.